Multimodal biomarker panels incorporating inflammatory mediators (e.g., CXCL10, IL-23, TNF-α), bone and cartilage turnover products, and genetic risk variants are under active investigation for their potential to identify psoriasis patients at highest risk for PsA development and to guide personalized treatment [65,66,68]. This evidence concerns the gene TNF and psoriasis.